ImCheck Therapeutics receives EMA Orphan Drug Designation for ICT01 for treatment for acute myeloid leukemia: Marseille, France Thursday, July 24, 2025, 15:00 Hrs [IST] ImCheck Th ...

French biotech ImCheck Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A ...

Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...

ImCheck Therapeutics just raised $103 million to treat multiple forms of cancer. The company is working on one of the fastest-growing ideas in cancer research: gamma-delta T cells.

ImCheck Therapeutics’ contribution is a type of drug that could bring advantages over the first generation of cancer immunotherapies. Now the biotech has €96M that will help continue clinical ...

ImCheck Therapeutics raises €20 Million and appoints its CEO Emerging leader in immuno-oncology accelerates its development programs and prepares for entry into the clinic Marseille, France, May ...

ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023Interim data from Phase I dose escalation portion of ...

With all that on the to-do list, ImCheck Therapeutics has refueled with a 96 million euro ($101 million) funding round that featured existing investors Pfizer, Gimv and more.

Marseille, France, May 22, 2025, 5:00 pm ET/11:00 pm CET – ImCheck Therapeutics today announced the publication of its abstract for an upcoming oral presentation at the 2025 American Society of ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...